Standardized therapy management system used for hematological malignancy patients

Abstract

A standardized therapy management system used for hematological malignancy patients comprises a data base, a recording module, an evaluation module and a statistics module. The standardized therapy management system used for hematological malignancy patients comprehensively records disease information of the patients; provides standardized therapy, evaluation procedure and examination and testing methods; and manages therapeutic evaluation time and reexamination time nodes of the patients in standardized mode. Doctors can improve the capability of clinician standardized therapy management through the statistics module, work omissions caused by inadequate experience and negligence can be reduced, and state, curative effect and prognoses of the hematological malignancy patients can be evaluated through the evaluation module.

Description

technical field [0001] The invention relates to the medical field, in particular to a disease treatment management system. Background technique [0002] Hematological malignancies, including leukemia, lymphoma, and myeloma, are characterized by long treatment cycles, complex treatment plans, and various efficacy evaluation criteria. On the one hand, due to the characteristics of the disease itself, patients need to return to the hospital for long-term and repeated treatment. On the other hand, due to the in-depth understanding of the disease, it is necessary to have a reasonable judgment on the previous treatment effect. At present, the medical evaluation of the treatment and curative effect of malignant hematological diseases mainly depends on the summarization of doctors' own experience. Most clinicians are exposed to busy medical work and lack comprehensive and systematic summary and evaluation of patients with malignant hematological diseases admitted to hospital. Influ...

AI Technical Summary

Problems solved by technology

At present, the medical evaluation of the treatment and curative effect of malignant hematological diseases mainly depends on the summarization of doctors' own experience. Most clinicians are exposed to busy medical work and lack comprehensive and systematic summary and evaluation of patients with malignant hematological diseases admitted to hospital. Influenced by the speed of knowledge update, some treatment methods and prognosis evaluation standards obviously lag behind the international treatment and evaluation progress, resulting in invalid evaluation and over-treatment of patients, etc.

[0003] Traditional patient disease treatment management mainly relies on the simple paper-based medical record summary of the doctor after the patient's first admission. Its shortcomings are: 1. Lack of system and coherence: the formulation of the patient's treatment plan is mainly based on the disease state at the time of admission , the understanding of the evolution of the patient’s disease is not enough, if the patient changes doctors or hospitals during the treatment process, the continuity of treatment and follow-up cannot be guaranteed; 2. The risk and efficacy evaluation systems of different diseases are significantly different: doctors need to understand each disease in detail The detailed content of the evaluation system is a heavy task; 3. The evaluation time nodes and curative effect standards may be uneven due to differences in understanding; 4. Follow-up items and return to hospital treatment time need to be managed in a standardized manner to avoid some patients who do not have a strong sense of time Insufficient attention to the disease and the occurrence of serious complications and disease recurrence; 5. Unable to realize the access and statistics of clinically effective data: the information related to patient treatment in the clinical medical records is different due to the recording habits of different doctors, and some cases There will be a lack of key information for disease assessment, and the current clinically applicable electronic medical record system cannot effectively access the effective data of diagnosis, treatment and follow-up assessment of hematologic malignancies

Images